Medicines Law & Policy releases analysis, tools, and data to influence policy and practices to improve access to medicines.

Our research

ML&P delves into complex public health issues, seeking to make the legal implications of international legislation clearer, and to...

Blog

Medicines Law & Policy periodically will post timely analysis and insight into current events related to intellectual property and...

TRIPS Flexibilities Database

The TRIPS Flexibilities Database contains instances when authorities have invoked, planned to invoke, or have been asked to invoke...

Latest Blog Posts from Medicines Law & Policy

US Authorisation of Non-Voluntary Use of Patents frequently used for health technologies

During the Covid-19 pandemic, the United States prioritised the rapid development of products needed to combat the health crisis.  Rapid product development was pursued...

European Parliament’s amendments make the Regulation for EU-wide compulsory licensing difficult to use and need to be rolled back

European Parliament legislative resolution of 13 March 2024, on the proposal for a regulation of the European Parliament and of the Council on compulsory...

Worldwide licensing of pandemic technologies is already current practice. The Pandemic Accord should protect it.

The negotiations for a WHO pandemic accord are still in full swing this week. Talks are taking place behind closed doors, but it is...

Intervention at Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement or other international instrument on pandemic prevention, preparedness and response, 9th...

The following intervention was delivered by Ellen 't Hoen on 18 March, 2024 Download this statement as a PDF here. Thank you for the opportunity to...

Something is going terribly wrong with the EU Compulsory Licensing Regulation

This week the European Parliament will vote on amendments to the Commission’s proposed regulation of the European Parliament and the Council on compulsory licensing...

It is not too late to solve the know-how problem in the WHO Pandemic Accord

Introduction One of the most important Intellectual Property (IP) problems which the Pandemic Accord negotiators need to solve is now in danger of being completely...

Written remarks submitted to the OHCHR following the Expert Workshop on the key challenges and new developments in ensuring access to medicines, vaccines and...

This blog was submitted by Dr. Katrina Perehudoff, Law Centre for Health and Rights at the University of Amsterdam, and Medicines Law & Policy,...

Medicines Law & Policy Intervention at the WHO Pandemic Accord Negotiations

This statement was delivered on 19 February at the World Health Organization in Geneva, on the occasion of the 8th Intergovernmental Negotiating Body to...

Commission report on competition enforcement in the pharmaceutical sector

Guest author Jacquelyn D. Veraldi is Assistant Professor of European Law at the University of Groningen. Guest author Tais A. Ruiz Palacios is a...

To achieve fair pricing: Ensure cooperation and transparency, build enforcement capacity, and engage civil society

Greater cooperation, clarity and capacity can help create a supportive environment for the private sector to fairly price their products. The first condition is cooperation...

Twitter

Research Highlights

Posts by Topic